Systemic Therapy for Esophageal Squamous Cell Carcinoma.
With more understanding of the tumor biology, esophageal squamous cell carcinoma (ESCC) and adenocarcinoma are increasingly recognized as different disease entities and are managed with different treatment approaches. Most patients with ESCC need systemic treatment at some point of their disease course, but only until recently, the progress in systemic treatment has been relatively stagnant compared with its adenocarcinoma counterpart. Platinum-based regimens remain the standard of care, while taxanes have been increasingly used upfront and in later lines of treatment. The attempts to personalize treatment for ESCC with various target therapies have been futile. Immune checkpoint inhibitors are now coming into play with promising activity and potentials to combine with different treatment modalities. The current chapter overviews the systemic treatment for ESCC and highlights the recent development.
['Lam|Ka On|KO|', 'Chan|Wendy W L|WWL|', 'So|Tsz Him|TH|', 'Kwong|Dora L W|DLW|']
D000230:Adenocarcinoma D002294:Carcinoma, Squamous Cell D045744:Cell Line, Tumor D004938:Esophageal Neoplasms D000077277:Esophageal Squamous Cell Carcinoma D006258:Head and Neck Neoplasms D006801:Humans D009062:Mouth Neoplasms
Esophageal squamous cell carcinoma Target therapy Immune checkpoint inhibitor Chemotherapy